3Arias CA, Murray BE. Antibiotic-resistant bugs in the 21st century-a clinical super-challenge[J]. N Engl J Med, 2009, 360(5) : 439-443.
4Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing[S]. Tweenty-first in- formational supplement, 2011, M100-S21 Vol 31 No. 1.
5Falagas ME, Giannopoulou KP, Kokolakis GN, et al. Fosfo- mycin: use beyond urinary tract and gastrointestinal infec tions[J]. Clin Infect Dis, 2008, 46(7): 1069-1077.
6Olsson-Liljequist B, Burman LG. Introducing fosfomycin for surgical prophylaxis-emergence of resistance in aerobic faecal gram-negative bacteria of in patients, but not among strains causing infection after elective colorectal procedures [J ]. Scand J Infect Dis, 1993, 25(6) :725-733.
7Andaker L, Burman LG, Eklund A, et al. Fosfomycin/met- ronidazole compared with doxycycline/metronidazole for the prophylaxis of infection after elective coloreetal surgery: a randomised double blind multicentre trial in 517 patients[J]. Eur J Surg, 1992, 158(3):181 185.
8Nohr M, Andersen JC, Juul-Jensen KE. Prophylactic single dose fosfomycin and metronidazole compared with neomycin, haeitraein, metronidazole and ampicillin in elective colorectal operations[J]. Acta Chir Seand, 1990, 156(3):223-230.
9Lindhagen J, Hadziomerovic A, Nordlung S, et al. Comparison of systemic prophylaxis with metronidazole-fosfomycin and met- ronidazole-cephalothin in elective colorectal surgery[J]. Acta Chir Scand, 1981, 147(4):277-283.
